|
|
|
Volumn 37, Issue 2, 2007, Pages 625-660
|
|
The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ISOTRETINOIN;
ACNE VULGARIS;
ARTICLE;
CONGENITAL MALFORMATION;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG CONTRAINDICATION;
DRUG CONTROL;
DRUG EFFECT;
DRUG SURVEILLANCE PROGRAM;
ECONOMICS;
FEMALE;
FETOMATERNAL TRANSFUSION;
FETUS;
FOOD AND DRUG ADMINISTRATION;
HISTORY;
HUMAN;
INSTRUMENTATION;
LAW;
MALE;
METHODOLOGY;
ORGANIZATION AND MANAGEMENT;
PHARMACY;
PRACTICE GUIDELINE;
PREGNANCY;
RISK MANAGEMENT;
SEXUAL BEHAVIOR;
SKIN DISEASE;
SOCIAL CONTROL;
STANDARD;
UNITED STATES;
ABNORMALITIES, DRUG-INDUCED;
ACNE VULGARIS;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
COST-BENEFIT ANALYSIS;
DRUG AND NARCOTIC CONTROL;
DRUG APPROVAL;
FEMALE;
FETUS;
GUIDELINES;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
ISOTRETINOIN;
LEGISLATION, PHARMACY;
MALE;
MATERNAL-FETAL EXCHANGE;
PHARMACEUTICAL SERVICES;
PREGNANCY;
REPRODUCTIVE BEHAVIOR;
RISK MANAGEMENT;
SKIN DISEASES;
SOCIAL CONTROL POLICIES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33847744224
PISSN: 05865964
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|
